Literature DB >> 31235075

Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus.

Merav Heshin-Bekenstein1, Laura Trupin2, Ed Yelin3, Emily von Scheven4, Jinoos Yazdany5, Erica F Lawson4.   

Abstract

OBJECTIVES: Determine whether adults with childhood-onset systemic lupus erythematosus (cSLE) are at increased risk for disease- and steroid-related damage as compared to individuals with adult-onset SLE (aSLE), and whether they continue to accumulate disease damage in adulthood.
METHODS: Data derive from the 2007-2015 cycles of the Lupus Outcomes Study, a longitudinal cohort of adults with confirmed SLE. The Brief Index of Lupus Damage (BILD), a validated, patient-reported measure, was used to assess SLE-associated damageParticipants with baseline BILD were included (N = 1035). Diagnosis at age < 18 years was defined as cSLE (N = 113). Outcome variables included BILD score at baseline and follow-up, clinically significant change in BILD score over follow-up period, and presence of steroid-related damage (cataracts, osteoporosis-related fracture, avascular necrosis or diabetes mellitus).
RESULTS: Mean time between baseline and follow up BILD assessment was 6.3 ± 1.7 years. In adjusted analyses, participants with cSLE and aSLE had similar levels of disease-related damage, and accumulated damage at similar rates. Participants with cSLE were more likely to report steroid-related damage (OR 1.7, 95% CI 1.1-2.8) in the adjusted analysis as compared to those with aSLE. Likelihood of steroid-related damage increased with disease duration for both groups, but was consistently higher among cSLE participants.
CONCLUSION: In this longitudinal cohort of adults with SLE, participants continued to accumulate damage at similar rates over time, regardless of age at onset or disease duration. Childhood-onset predicted increased risk of steroid-related damage. Aggressive use of steroid-sparing treatment strategies during childhood may be important to prevent steroid-related damage in adulthood.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adult-onset systemic lupus erythematosus; Brief Index of Lupus Damage (BILD) score; Childhood-onset systemic lupus erythematosus; Disease related damage; Steroid related damage

Mesh:

Substances:

Year:  2019        PMID: 31235075     DOI: 10.1016/j.semarthrit.2019.05.010

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  9 in total

Review 1.  Functional Characteristics and Application of Mesenchymal Stem Cells in Systemic Lupus Erythematosus.

Authors:  Wen-Yan Tang; Jia-Hua Liu; Chun-Jin Peng; Yao Liao; Jie-Si Luo; Xi Sun; Yan-Lai Tang; Xue-Qun Luo
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-03-13       Impact factor: 4.291

Review 2.  Systemic Lupus Erythematosus in Children and Young People.

Authors:  A Charras; E Smith; C M Hedrich
Journal:  Curr Rheumatol Rep       Date:  2021-02-10       Impact factor: 4.592

3.  Nailfold capillary abnormalities in childhood-onset systemic lupus erythematosus: a cross-sectional study compared with healthy controls.

Authors:  Dieneke Schonenberg-Meinema; Sandy C Bergkamp; Amara Nassar-Sheikh Rashid; Leontien B van der Aa; Godelieve J de Bree; Rebecca Ten Cate; Maurizio Cutolo; A Elisabeth Hak; Petra Ce Hissink Muller; Marieke van Onna; Taco W Kuijpers; Vanessa Smith; J Merlijn van den Berg
Journal:  Lupus       Date:  2021-03-03       Impact factor: 2.911

Review 4.  Kidney outcomes for children with lupus nephritis.

Authors:  Louise Oni; Rachael D Wright; Stephen Marks; Michael W Beresford; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2020-07-28       Impact factor: 3.714

5.  Prognostic Factors at Diagnosis Associated With Damage Accrual in Childhood-Onset Systemic Lupus Erythematosus Patients.

Authors:  Ana Luisa Rodríguez-Lozano; Francisco Eduardo Rivas-Larrauri; Silvestre García-de la Puente; Daniel Alfredo Alcivar-Arteaga; Alejandro Gabriel González-Garay
Journal:  Front Pediatr       Date:  2022-04-22       Impact factor: 3.418

6.  An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Vitor Cavalcanti Trindade; Magda Carneiro-Sampaio; Eloisa Bonfa; Clovis Artur Silva
Journal:  Paediatr Drugs       Date:  2021-07-10       Impact factor: 3.022

7.  Avascular necrosis less frequently found in systemic lupus erythematosus patients with the use of alternate day corticosteroid

Authors:  Ismail Doğan; Umut Kalyoncu; Levent Kiliç; Ali Akdoğan; Ömer Karadağ; Sedat Kiraz; Şule A Bilgen; Ihsan Ertenli
Journal:  Turk J Med Sci       Date:  2020-02-13       Impact factor: 0.973

8.  'It is good to have a target in mind': qualitative views of patients and parents informing a treat to target clinical trial in juvenile-onset systemic lupus erythematosus.

Authors:  Eve M D Smith; Sarah L Gorst; Eslam Al-Abadi; Daniel P Hawley; Valentina Leone; Clarissa Pilkington; Athimalaipet V Ramanan; Satyapal Rangaraj; Arani Sridhar; Michael W Beresford; Bridget Young
Journal:  Rheumatology (Oxford)       Date:  2021-12-01       Impact factor: 7.580

9.  International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis.

Authors:  Nathalie E Chalhoub; Scott E Wenderfer; Deborah M Levy; Kelly Rouster-Stevens; Amita Aggarwal; Sonia I Savani; Natasha M Ruth; Thaschawee Arkachaisri; Tingting Qiu; Angela Merritt; Karen Onel; Beatrice Goilav; Raju P Khubchandani; Jianghong Deng; Adriana R Fonseca; Stacy P Ardoin; Coziana Ciurtin; Ozgur Kasapcopur; Marija Jelusic; Adam M Huber; Seza Ozen; Marisa S Klein-Gitelman; Simone Appenzeller; André Cavalcanti; Lampros Fotis; Sern Chin Lim; Rodrigo M Silva; Julia Ramírez- Miramontes; Natalie L Rosenwasser; Claudia Saad-Magalhaes; Dieneke Schonenberg-Meinema; Christiaan Scott; Clovis A Silva; Sandra Enciso; Maria T Terreri; Alfonso-Ragnar Torres-Jimenez; Maria Trachana; Sulaiman M Al-Mayouf; Prasad Devarajan; Bin Huang; Hermine I Brunner
Journal:  Arthritis Rheumatol       Date:  2022-01-04       Impact factor: 10.995

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.